Bristol-Myers Squibb (NYSE:BMY) Given Neutral Rating at Cantor Fitzgerald

Bristol-Myers Squibb (NYSE:BMY - Get Free Report)'s stock had its "neutral" rating reaffirmed by analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday, Marketbeat Ratings reports. They currently have a $55.00 target price on the biopharmaceutical company's stock. Cantor Fitzgerald's price target suggests a potential upside of 14.92% from the company's previous close. Cantor Fitzgerald also issued estimates for Bristol-Myers Squibb's FY2025 earnings at $6.81 EPS.

Other equities research analysts have also recently issued research reports about the company. UBS Group cut their price target on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a report on Friday, April 11th. The Goldman Sachs Group reissued a "neutral" rating and issued a $55.00 price target (down previously from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Piper Sandler began coverage on shares of Bristol-Myers Squibb in a research report on Tuesday. They set an "overweight" rating and a $65.00 price target on the stock. Truist Financial increased their price objective on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Finally, Citigroup lifted their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research report on Tuesday, January 28th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, Bristol-Myers Squibb currently has an average rating of "Hold" and a consensus price target of $58.00.

Bristol-Myers Squibb Stock Performance

Bristol-Myers Squibb stock traded down $0.83 during mid-day trading on Tuesday, hitting $47.86. The company had a trading volume of 16,292,011 shares, compared to its average volume of 12,961,714. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The company has a market capitalization of $97.38 billion, a price-to-earnings ratio of -10.83, a P/E/G ratio of 2.07 and a beta of 0.41. The company's fifty day moving average is $56.37 and its 200-day moving average is $56.47. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.55 by $0.25. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. During the same quarter last year, the business earned ($4.40) earnings per share. Equities research analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 1,823 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The stock was purchased at an average price of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the purchase, the executive vice president now directly owns 63,932 shares in the company, valued at $3,506,030.88. This trade represents a 2.94 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.09% of the company's stock.

Institutional Investors Weigh In On Bristol-Myers Squibb

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Alta Advisers Ltd increased its holdings in shares of Bristol-Myers Squibb by 50.4% in the first quarter. Alta Advisers Ltd now owns 10,150 shares of the biopharmaceutical company's stock valued at $619,000 after purchasing an additional 3,400 shares during the period. Lodestar Private Asset Management LLC increased its stake in shares of Bristol-Myers Squibb by 12.0% during the first quarter. Lodestar Private Asset Management LLC now owns 5,093 shares of the biopharmaceutical company's stock worth $311,000 after acquiring an additional 545 shares during the period. Cypress Capital LLC boosted its holdings in Bristol-Myers Squibb by 1.0% in the 1st quarter. Cypress Capital LLC now owns 48,067 shares of the biopharmaceutical company's stock valued at $2,932,000 after purchasing an additional 479 shares in the last quarter. Benchmark Financial Wealth Advisors LLC increased its position in Bristol-Myers Squibb by 8.8% during the 1st quarter. Benchmark Financial Wealth Advisors LLC now owns 22,566 shares of the biopharmaceutical company's stock worth $1,376,000 after purchasing an additional 1,823 shares during the period. Finally, Deseret Mutual Benefit Administrators raised its position in Bristol-Myers Squibb by 9.6% in the first quarter. Deseret Mutual Benefit Administrators now owns 14,313 shares of the biopharmaceutical company's stock worth $873,000 after acquiring an additional 1,257 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.